FI963805A - Recombinant adenoviruses encoding a neurotrophic factor from glial cells (GDNF) - Google Patents

Recombinant adenoviruses encoding a neurotrophic factor from glial cells (GDNF) Download PDF

Info

Publication number
FI963805A
FI963805A FI963805A FI963805A FI963805A FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A
Authority
FI
Finland
Prior art keywords
gdnf
recombinant adenoviruses
adenovirus
cell
dna sequence
Prior art date
Application number
FI963805A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI963805A0 (en
Inventor
Philippe Horellou
Jacques Mallet
Michel Perricaudet
Frederic Revah
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI963805A publication Critical patent/FI963805A/en
Publication of FI963805A0 publication Critical patent/FI963805A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic growth factor (GDNF) are provided. The recombinant adenoviruses are useful in a method of expressing GDNF in a cell, wherein the cell is present in a mammal suffering from Parkinson's disease, comprising infecting said cell with a replication-defective recombinant adenovirus comprising a DNA sequence encoding GDNF operably linked to a promoter by administering the adenovirus into cells of the central nervous system. The recombinant adenoviruses of the invention are also useful in a method of treating Parkinson's disease comprising administering into cells of the central nervous system of a mammal suffering therefrom a replication defective recombinant adenovirus comprising ITRs, an encapsidation sequence and a DNA sequence encoding GDNF operably linked to a promoter, wherein the adenovirus E1 gene is non-functional and GDNF is expressed at a level that provides a therapeutic effect.
FI963805A 1994-03-25 1996-09-24 Recombinant adenoviruses encoding a neurotrophic factor from glial cells (GDNF) FI963805A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403542A FR2717824B1 (en) 1994-03-25 1994-03-25 Recombinant viruses, preparation and use in gene therapy.
PCT/FR1995/000356 WO1995026408A1 (en) 1994-03-25 1995-03-23 Recombinant adenoviruses coding for glial-derived neurotrophic factor (gdnf)

Publications (2)

Publication Number Publication Date
FI963805A true FI963805A (en) 1996-09-24
FI963805A0 FI963805A0 (en) 1996-09-24

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963805A FI963805A0 (en) 1994-03-25 1996-09-24 Recombinant adenoviruses encoding a neurotrophic factor from glial cells (GDNF)

Country Status (14)

Country Link
US (1) US6245330B1 (en)
EP (1) EP0752004B1 (en)
JP (1) JPH09510620A (en)
KR (1) KR100403707B1 (en)
AT (1) ATE335832T1 (en)
AU (1) AU704910B2 (en)
CA (1) CA2184841C (en)
DE (1) DE69535155T2 (en)
FI (1) FI963805A0 (en)
FR (1) FR2717824B1 (en)
IL (1) IL113109A0 (en)
MX (1) MX9604024A (en)
WO (1) WO1995026408A1 (en)
ZA (1) ZA952433B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (en) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa METHOD OF TREATING AMYOTROPHIC SIDE SCLEROSIS
WO1998046737A2 (en) * 1997-04-15 1998-10-22 University Of Medicine And Dentistry Of New Jersey cDNA FOR HUMAN GDNF AND PROMOTER THEREFOR WHICH ALLOWS REGULATED AND CONSTITUTIVE EXPRESSION
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (en) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-encoding DNA, parts thereof and GDNF variants
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
WO2003055983A2 (en) * 2001-12-21 2003-07-10 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
EP1694313A4 (en) * 2003-12-18 2010-11-17 Biomas Ltd Tellurium derivatives for prevention and treatment of neurodegenerative processes
BRPI0710800A2 (en) 2006-04-25 2012-01-17 Univ California administration of growth factors for the treatment of snc disorders
JP2009535360A (en) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutic agents
WO2008154644A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
MX2010012592A (en) 2008-05-20 2011-05-05 Eos Neuroscience Inc Vectors for delivery of light-sensitive proteins and methods of use.
US20140259192A1 (en) 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
WO2019174697A1 (en) 2018-03-15 2019-09-19 Coloplast A/S Apparatus and methods for navigating ostomy appliance user to changing room

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2702152B1 (en) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Recombinant viruses and their use in gene therapy.

Also Published As

Publication number Publication date
FR2717824A1 (en) 1995-09-29
ZA952433B (en) 1996-01-15
EP0752004B1 (en) 2006-08-09
DE69535155T2 (en) 2007-06-28
AU2141195A (en) 1995-10-17
DE69535155D1 (en) 2006-09-21
JPH09510620A (en) 1997-10-28
WO1995026408A1 (en) 1995-10-05
CA2184841A1 (en) 1995-10-05
KR100403707B1 (en) 2004-02-11
EP0752004A1 (en) 1997-01-08
FI963805A0 (en) 1996-09-24
MX9604024A (en) 1997-09-30
US6245330B1 (en) 2001-06-12
ATE335832T1 (en) 2006-09-15
FR2717824B1 (en) 1996-04-26
CA2184841C (en) 2009-08-18
KR970702373A (en) 1997-05-13
IL113109A0 (en) 1995-06-29
AU704910B2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
FI963805A (en) Recombinant adenoviruses encoding a neurotrophic factor from glial cells (GDNF)
Wang et al. Tendon healing in vitro: genetic modification of tenocytes with exogenous PDGF gene and promotion of collagen gene expression
Korte et al. Virus-mediated gene transfer into hippocampal CA1 region restores long-term potentiation in brain-derived neurotrophic factor mutant mice.
Akimoto et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.
Barkats et al. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases
Leslie et al. Nerve growth factor contributes to the up-regulation of growth-associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation
Cantini et al. Macrophages regulate proliferation and differentiation of satellite cells
Ebendal Function and evolution in the NGF family and its receptors
Ono et al. Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice
AU712775B2 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
Ebendal NGF in CNS: experimental data and clinical implications
JP2702811B2 (en) Modified ciliary neurotrophic factor
Haase et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action
Davies Paracrine and autocrine actions of neurotrophic factors
CA2243261A1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
WO1997026337B1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
Tuszynski et al. Central infusions of brain-derived neurotrophic factor and neurotrophin-45, but not nerve growth factor and neurotrophin-3, prevent loss of the cholinergic phenotype in injured adult motor neurons
EP1674108A3 (en) Osteoporosis treatment
Houlgatte et al. Levels of nerve growth factor secreted by rat primary fibroblasts and iris transplants are influenced by serum and glucocorticoids
Sauer et al. Brain-derived neurotrophic factor and neurotrophin-45 modify neurotransmitter-related gene expression in the 6-hydroxydopamine-lesioned rat striatum
Horellou et al. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease
Robert et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases
CN1155706C (en) Method for treating amyotrophic lateral sclerosis
Horellou et al. In VivoAdenovirus-Mediated Gene Transfer for Parkinson's Disease
Noel et al. The stimulation of fibroblasts collagen synthesis by neoplastic cells is modulated by the extracellular matrix

Legal Events

Date Code Title Description
MA Patent expired